Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.81 |
| ▸ | RAB9A | P51151 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.79 |
| ▸ | TP53 | P04637 | 5/20 | 0.79 |
| ▸ | MEN1 | O00255 | 5/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | PKM | P14618 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.76 |
| ▸ | RELA | Q04206 | 1/20 | 0.76 |
| ▸ | AR | P10275 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802217 | 0.89 | NPC1 (0.83) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7824945 | 0.88 | KMT2A (0.82) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5345650 | 0.87 | KMT2A (1.00) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8363735 | 0.87 | NPC1 (1.00) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5400469 | 0.87 | AR (0.89) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL12167724 | 0.87 | AR (0.89) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5226157 | 0.86 | NPC1 (1.00) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL15838878 | 0.85 | NPC1 (0.60) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30949327 | 0.85 | AR (0.87) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30455725 | 0.85 | NPC1 (0.76) | NPC1RAB9AALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| US-7230020-B2 | 11β-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2007-06-12 | — | — | US | disclosed |
| EP-1675844-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | Sterix Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2005-10-13 | — | — | US | disclosed |
| WO-2005042513-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | STERIX LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD17B3 | NPC1 1239/4885RAB9A 3856/4885ALDH1A1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.